Arizona officials are moving to restrict government employees from using nonpublic information to wager on prediction markets, Axios reports, a sign that public-sector ethics rules are starting to catch up with the industry’s growth. The move follows several high-profile insider-betting controversies and puts a sharper regulatory spotlight on a core question for prediction markets: who should be allowed to trade when the outcome may be influenced by privileged information?
Arizona treats prediction markets as an ethics risk
Axios reports that Arizona agencies are adopting policies aimed at barring government employees from wagering with nonpublic information. That matters because prediction markets increasingly list contracts tied to elections, policy, public health, geopolitics, and other areas where officials may have access to information before the public does.
For market operators, the Arizona move underscores that compliance will not only come from federal regulators. State agencies, employers, and ethics offices may increasingly write their own rules governing employee participation.
Kalshi’s World Cup market shows the scale problem is here
Fortune reported that Kalshi’s Argentina-Spain World Cup final contract topped $1.27 billion in trading volume, making it the largest single prediction market in the platform’s history.
That figure is a milestone for the industry. Prediction markets are no longer niche curiosity products; major sports and cultural events can now attract volumes comparable to mainstream betting and trading venues. But scale cuts both ways: the bigger the market, the more attention it draws from regulators, media, and integrity monitors.
Kalshi moves into clinical trials and FDA decisions
Reuters via Investing.com reports that Kalshi plans to launch markets on late-stage clinical trial outcomes and FDA decisions in partnership with AppliedXL. Kalshi said the markets would include employment verification and bans on trading with material nonpublic information.
This is one of the clearest tests yet of whether prediction markets can handle sensitive, information-heavy categories. Drug approvals and trial results are precisely the kind of events where expert insight can improve price discovery — but also where insider-information risks are acute.
Polymarket seeks a legal path to margin in the U.S.
Bloomberg Law reports that Polymarket is seeking U.S. regulatory approval to offer margin trading through an affiliate application as a futures commission merchant, along with related CFTC rulebook changes.
If approved, that would mark a significant step toward a more formal U.S. operating structure for Polymarket-style trading. It also shows that major platforms are increasingly trying to build within regulated frameworks rather than operate around them.
Why it matters
The industry’s biggest theme is convergence: prediction markets are becoming larger, more financialized, and more entangled with real-world institutions. Arizona’s ethics push, Kalshi’s massive World Cup volume, its expansion into FDA-linked markets, and Polymarket’s margin effort all point in the same direction — prediction markets are growing up, and oversight is arriving with them.